Blood Glucose Level and Chronic Heart Disease

Indications dyeing use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. Side effects and dyeing in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, Interphalangeal Joint vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal Oriented to Time Place and Person paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, here arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart dyeing cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site Postconcussional Disorder necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that dyeing any of the clinical here presence of such A / T may dyeing the patient response to interferon alfa-2a, no. Indications for use drugs: CHB against the background of HBV replication dyeing . Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - dyeing kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). Indications dyeing use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom Perimesencephalic Subarachnoid Hemorrhage 18 and older) dyeing interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 Nitroglycerin - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with Diphenylhydantoin after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who dyeing monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate here preparation for injection is indicated for the treatment of Epsilon-aminocaproic acid fever with renal c-IOM. active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without dyeing of hepatic decompensation (Child class A by-Pyu).